Skip to content

Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study

Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03339245
Enrollment
13
Registered
2017-11-13
Start date
2017-12-05
Completion date
2018-10-02
Last updated
2021-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Alcoholic Fatty Liver Disease, Obesity

Keywords

obesity, fructose, glucose, fecal microbiota, intestinal permiability, fecal metabolites

Brief summary

Non alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver function tests in the U.S. (Browning, et al., 2004), ranging from steatosis to end-stage liver disease. Fructose ingestion by the American public has steadily increased since the 1980's, and with it increases in NAFLD, fatty liver hepatitis (NASH), diabetes, obesity, and cardiovascular disease. Foods and beverage in the U.S. are typically sweetened with sucrose (50% glucose and 50% fructose) or high fructose corn syrup (45-58% glucose and 42-55% fructose) (Stanhope, et al., 2009). Research into the role that added fructose plays in the emerging chronic health issues is necessary to affect public policy and provide the connection between fructose and the increasing incidence of these co-morbidities. There is evidence that gut bacteria contribute to a range of human diseases including those of the liver and gastrointestinal tract. Dietary fructose has been suggested to play a role in the development of these diseases and has been shown to alter gut microbes in animals. If the investigators find that dietary fructose alters bacteria in the human gut, this would suggest a potential targetable link between high fructose diet and disease.

Detailed description

Non- alcoholic fatty liver disease (NAFLD) occurs in 30% of the adult US population (Luther, J., et al., 2015). Eating large amounts of fructose (a dietary sugar) increases liver fat accumulation and worsens NAFLD. In addition, fructose consumption has been shown to greatly increase triglycerides(fat) in the blood after meals, increasing the risk of heart disease,(Stanhope,et al., 2009) insulin resistance and diabetes. Current theories on liver disease caused by consuming fructose focuses on changes in the breakdown of fat by the liver. In experimental animals, fructose feeding changes the bacteria population (microbiota) in the gut, causes NAFLD and NASH, and increases leaking of toxins from the intestine (intestinal permeability) to the blood stream resulting in inflammation. In humans, fructose consumption rapidly increases liver fat. However, changes in gut microbiota have not been studied. The proposed study will compare the addition of fructose or glucose to the study subjects' usual diet in a crossover design. They will not know which sugar they are receiving. The Investigators plan to study postmenopausal, moderately obese but healthy women, and moderately obese but healthy men (age 45-70 years) to find out the effect of fructose verses glucose on the bacteria in their stool and inflammation in the bowel. The Investigators hypothesize that adding fructose to the participant's usual diet, compared to glucose, will change stool bacteria composition and the products that the bacteria produce, which may increase intestinal leakage, and increase markers of inflammation in the stool and blood due to this leakage. These changes may contribute to fructose -induced liver disease.

Interventions

OTHERFructose Solution (75 Grams)

Fructose given in divided doses at breakfast and dinner.

OTHERGlucose Solution (75 grams)

Glucose given in divided doses at breakfast and dinner.

Sponsors

Weill Medical College of Cornell University
CollaboratorOTHER
National Institutes of Health (NIH)
CollaboratorNIH
Rockefeller University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Masking description

Double blind

Eligibility

Sex/Gender
ALL
Age
45 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Post menopausal female, last menstrual period at least 24 months ago OR male * Age 45-70 * Willing to consume usual diet with either fructose or glucose added during (2) 16-18 day inpatient stays * Willing to consume usual diet during 2 week wash-out period at home * BMI 30.0-39.9 * Willingness not to travel long distances while on study, including wash-out period * Willingness not to be exposed to new pets while on study including wash-out period

Exclusion criteria

* Fasting serum triglycerides \>200mg/dl * Fasting blood glucose \>126mg/dl * Renal function tests \>2x Upper limit of normal * Liver Function Tests \> 1.5x Upper limit of normal * Currently on statins * Daily use of a cathartic * Broad spectrum antibiotic use within the past 45 days * Currently on proton pump inhibitor * Currently on insulin or oral hypoglycemic agents * Active viral Hepatitis * Chronic constipation * Inflammatory bowel disease * Chronic diarrhea * GI resection * Any evidence of cardiovascular disease on EKG * History of cardiovascular disease such as coronary artery disease, Coronary Artery Bypass Graft, valve replacement, Myocardial Infarction, stroke / Transient Ischemic attack. * History of macronutrient malabsorption * Current smoker. Stopped \< 3 months ago. * Daily alcohol intake equal to 1.5 oz of 40 proof alcohol. * HIV positive * Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data * Persons taking probiotics

Design outcomes

Primary

MeasureTime frameDescription
Difference in the Distribution of Fecal Microbiota in Each Participantassessed at Day 16 of each intervention, up to 64 daysDifference in the distribution of fecal microbiota in each participant, between the fructose versus glucose supplemented diet arms of the study, as measured at the end of each intervention.

Countries

United States

Participant flow

Participants by arm

ArmCount
Glucose, Then Fructose
Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet. Fructose Solution (75 Grams): Fructose given in divided doses at breakfast and dinner. Glucose Solution (75 grams): Glucose given in divided doses at breakfast and dinner.
7
Fructose, Then Glucose
Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet. Fructose Solution (75 Grams): Fructose given in divided doses at breakfast and dinner. Glucose Solution (75 grams): Glucose given in divided doses at breakfast and dinner.
6
Total13

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event11
Overall StudyWithdrawal by Subject10

Baseline characteristics

CharacteristicGlucose, Then FructoseFructose, Then GlucoseTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
1 Participants2 Participants3 Participants
Age, Categorical
Between 18 and 65 years
6 Participants4 Participants10 Participants
Age, Continuous58 years57 years57.6 years
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants1 Participants2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
6 Participants5 Participants11 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
5 Participants4 Participants9 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
2 Participants2 Participants4 Participants
Region of Enrollment
United States
7 participants6 participants13 participants
Sex: Female, Male
Female
3 Participants3 Participants6 Participants
Sex: Female, Male
Male
4 Participants3 Participants7 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 40 / 6
other
Total, other adverse events
3 / 43 / 6
serious
Total, serious adverse events
0 / 40 / 6

Outcome results

Primary

Difference in the Distribution of Fecal Microbiota in Each Participant

Difference in the distribution of fecal microbiota in each participant, between the fructose versus glucose supplemented diet arms of the study, as measured at the end of each intervention.

Time frame: assessed at Day 16 of each intervention, up to 64 days

Population: Investigator has retired and access to results for each arm was not available for this outcome. Best efforts were made to obtain the data from the investigator; however, they were unsuccessful.

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026